6个非洲国家开始第2b阶段的阿尔卑斯(AlpE)试验, 这是一种新型的肺结核治疗。 BioVersys starts Phase 2b trial of AlpE, a new TB treatment, in six African countries.

生物维瑞斯已经开始AlpE的2b期试验,这是一种潜在的肺结核新疗法,在一项涉及六个非洲国家多达390名成年人的研究中,首位患者接受了该疗法. BioVersys has begun a Phase 2b trial of AlpE, a potential new treatment for pulmonary tuberculosis, dosing the first patient in a study involving up to 390 adults across six African countries. 为期20周的试验测试AlpE AlpE与标准的肺结核药物一起进行20周,目的是提高治疗效果和解决抗药性问题。 The trial tests AlpE alongside standard TB drugs over 20 weeks, aiming to improve treatment efficacy and address drug resistance. AlpE是BioVersysTRIC平台的一个小分子,在早期试验中显示出有希望的结果,并在美国和欧洲拥有孤儿药物的地位。 AlpE, a small molecule from BioVersys’s TRIC platform, showed promising results in earlier trials and holds orphan-drug status in the U.S. and Europe. 预计到2027年底将取得结果,并计划于2026年初进行结核病脑膜炎第二阶段试验。 Results are expected by late 2027, with a Phase 2 trial for TB meningitis planned for early 2026.